The results of Active Biotech’s rights issue show that 6,643,426 shares, which is about 96 percent of the shares offered, were subscribed for with subscription rights.
MGA Holding AB as the guarantor has subscribed remaining 272,596 shares. Through the rights issue, Active Biotech receives proceeds amounting to approximately SEK 55 million ($6M/€5.6M) before issue expenses.
As a result of the rights issue Active Biotech’s share capital increases by approximately SEK 26,068,856.73 ($2.85M/€2.7M) to approximately SEK 364,964,039.37 ($39,85M/€37.54M) and the total number of shares and votes increases by 6,916,022 to 96,824,320.
The company expects to start trading in the new shares on Nasdaq Stockholm about December 27, 2016.